Scientists report that antibodies that displayed high levels of cross-reactivity with the SARS-CoV-2 spike, were incapable of neutralizing pseudoviruses expressing SARS-CoV-2 spike proteins and were unlikely to mediate ADE via FcγRII receptor engagement.
[Scientific Reports]
6445218
{6445218:EQS4SDXT}
1
apa
50
default
1
163372
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22EQS4SDXT%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mannar%20et%20al.%22%2C%22parsedDate%22%3A%222021-06-14%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMannar%2C%20D.%2C%20Leopold%2C%20K.%2C%20%26amp%3B%20Subramaniam%2C%20S.%20%282021%29.%20Glycan%20reactive%20anti-HIV-1%20antibodies%20bind%20the%20SARS-CoV-2%20spike%20protein%20but%20do%20not%20block%20viral%20entry.%20%26lt%3Bi%26gt%3BScientific%20Reports%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B11%26lt%3B%5C%2Fi%26gt%3B%281%29%2C%2012448.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-91746-7%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-91746-7%26lt%3B%5C%2Fa%26gt%3B%20%26lt%3Ba%20title%3D%26%23039%3BCite%20in%20RIS%20Format%26%23039%3B%20class%3D%26%23039%3Bzp-CiteRIS%26%23039%3B%20data-zp-cite%3D%26%23039%3Bapi_user_id%3D6445218%26amp%3Bitem_key%3DEQS4SDXT%26%23039%3B%20href%3D%26%23039%3Bjavascript%3Avoid%280%29%3B%26%23039%3B%26gt%3BCite%26lt%3B%5C%2Fa%26gt%3B%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Glycan%20reactive%20anti-HIV-1%20antibodies%20bind%20the%20SARS-CoV-2%20spike%20protein%20but%20do%20not%20block%20viral%20entry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhiraj%22%2C%22lastName%22%3A%22Mannar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karoline%22%2C%22lastName%22%3A%22Leopold%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sriram%22%2C%22lastName%22%3A%22Subramaniam%22%7D%5D%2C%22abstractNote%22%3A%22The%20SARS-CoV-2%20spike%20glycoprotein%20is%20a%20focal%20point%20for%20vaccine%20immunogen%20and%20therapeutic%20antibody%20design%2C%20and%20also%20serves%20as%20a%20critical%20antigen%20in%20the%20evaluation%20of%20immune%20responses%20to%20COVID-19.%20A%20common%20feature%20amongst%20enveloped%20viruses%20such%20as%20SARS-CoV-2%20and%20HIV-1%20is%20the%20propensity%20for%20displaying%20host-derived%20glycans%20on%20entry%20spike%20proteins.%20Similarly%20displayed%20glycosylation%20motifs%20can%20serve%20as%20the%20basis%20for%20glyco-epitope%20mediated%20cross-reactivity%20by%20antibodies%2C%20which%20can%20have%20important%20implications%20on%20virus%20neutralization%2C%20antibody-dependent%20enhancement%20%28ADE%29%20of%20infection%2C%20and%20the%20interpretation%20of%20antibody%20titers%20in%20serological%20assays.%20From%20a%20panel%20of%20nine%20anti-HIV-1%20gp120%20reactive%20antibodies%2C%20we%20selected%20two%20%28PGT126%20and%20PGT128%29%20that%20displayed%20high%20levels%20of%20cross-reactivity%20with%20the%20SARS-CoV-2%20spike.%20We%20report%20that%20these%20antibodies%20are%20incapable%20of%20neutralizing%20pseudoviruses%20expressing%20SARS-CoV-2%20spike%20proteins%20and%20are%20unlikely%20to%20mediate%20ADE%20via%20Fc%5Cu03b3RII%20receptor%20engagement.%20Nevertheless%2C%20ELISA%20and%20other%20immunoreactivity%20experiments%20demonstrate%20these%20antibodies%20are%20capable%20of%20binding%20the%20SARS-CoV-2%20spike%20in%20a%20glycan-dependent%20manner.%20These%20results%20contribute%20to%20the%20growing%20literature%20surrounding%20SARS-CoV-2%20S%20cross-reactivity%2C%20as%20we%20demonstrate%20the%20ability%20for%20cross-reactive%20antibodies%20to%20interfere%20in%20immunoassays.%22%2C%22date%22%3A%222021-06-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-021-91746-7%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41598-021-91746-7%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-06-14T18%3A13%3A30Z%22%7D%7D%5D%7D
Mannar, D., Leopold, K., & Subramaniam, S. (2021). Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry. Scientific Reports, 11(1), 12448. https://doi.org/10.1038/s41598-021-91746-7 Cite

Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News